Valneva News

Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil

Lyon (France), Sao Paulo, (Brazil), February 3, 2026 – Valneva SE  (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world’s largest biomedical research centers, today announced the initiation of a Pilot Vaccination Strategy (PVS) in Brazil using Valneva’s single-shot chikungunya vaccine, IXCHIQ®. The pilot vaccination program will serve as the basis for post-marketing commitment studies evaluating the effectiveness and safety of IXCHIQ® in a real-world setting and generating real-world evidence in a large population.

UK cancels Covid vaccine deal with French firm Valneva

Saint-Herblain (France), September 13, 2021 – Valneva SE, a specialty vaccine company, today announced that it has received a termination notice from the UK Government (“HMG”) in relation to the Supply Agreement for its COVID-19 vaccine candidate, VLA2001. The contract provides HMG with the right to terminate. HMG has alleged that the Company is in breach of its obligations under the Supply Agreement, but the Company strenuously denies this.

Valneva is continuing its VLA2001 development plan. Testing for the Company’s pivotal Phase 3 trial, Cov-Compare, is ongoing at Public Health England (“PHE”). Valneva recently announced that its Phase 3 results are expected to be available early in the fourth quarter and that these results will form part of its rolling submission for conditional approval of VLA2001 with the UK’s Medicines and Healthcare products Regulatory Agency (“MHRA”). Subject to these data and MHRA approval, Valneva believes that initial approval for VLA2001 could be granted in late 2021.

Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine

Saint-Herblain (France), Sao Paulo, (Brazil), January 25, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, and Instituto Butantan, producer of immunobiologic products, today announced the signing of definitive agreements for the development, manufacturing and marketing of Valneva’s single-shot chikungunya vaccine, VLA1553, in Low and Middle Income Countries (LMICs). This finalization follows the signing of a binding term sheet in May 2020[1].  The collaboration falls within the framework of the $23.4 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2019.

Firm poised to produce 60 million Covid-19 vaccines for UK in 2021

Saint-Herblain (France), September 14th, 2020 – Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today announced a vaccine partnership with the UK government for its inactivated COVID-19 vaccine, VLA2001.

Under the agreement, if vaccine development is successful, Valneva will provide the UK government with 60 million doses in the second half of 2021. UK Government then has options over 40 million doses in 2022 and a further 30 million to 90 million doses, in aggregate, across 2023 to 2025. Revenue from these options could amount to almost €900 million. Valneva’s inactivated SARS-CoV-2 vaccine is expected to have a two dose regimen. UK government is also investing up-front in the scale up and development of the vaccine, with the investment being recouped against the vaccine supply under the partnership. The agreement follows the initial intent to participate in the UK Government’s COVID-19 vaccine response announced in July.

UK Agrees Joint Investment With Valneva to Boost Vaccine Production

LONDON — Britain has agreed a multi-million pound joint investment with French speciality vaccines company Valneva to upgrade a manufacturing facility and increase production capacity for a possible COVID-19 vaccine.

Britain said in July it had agreed in principle to buy 60 million doses of a Valneva vaccine, with an option to purchase 40 million more if it proved safe, effective and suitable.

The government did not disclose the exact size of the investment, and had previously said it was in talks about providing funding for the facility in Livingston, Scotland.

Valneva has previously said it is aiming for clinical trials of its vaccine to start in November or December this year.

Valneva Confirms Participation in UK Government COVID-19 Vaccine Response Program

Saint-Herblain (France), July 20th, 2020 – Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today confirmed its participation in the UK government COVID-19 vaccine response program.

Valneva has reached agreement in principle with the UK government to provide up to 100 million doses of its SARS-CoV-2 vaccine candidate, to be manufactured at its facilities in Livingston, Scotland. The UK government is expected to contribute to UK clinical studies costs and is negotiating funding to expand Valneva’s Scottish facility. As part of its broader COVID-19 response, Valneva plans to further invest in its manufacturing facility in Livingston, Scotland and also in Solna, Sweden.

Thomas Lingelbach, CEO of Valneva, commented, “We are delighted to have been selected to participate in this important program with the UK government. This recognizes the strong track record and capabilities that we have built in the last fifteen years both in the UK and beyond. Our Livingston facility has been FDA approved for over a decade and we have a strong team both there and in Solna. We also envisage manufacturing vaccines to support the need for prevention of COVID-19 beyond the UK.”

On April 22, 2020, Valneva announced that it is developing VLA2001, an inactivated whole virus vaccine candidate against the novel coronavirus SARS-CoV-2. VLA2001 leverages Valneva’s well-established platform for IXIARO®, its vaccine approved for active immunization for the prevention of Japanese encephalitis. The Company is also collaborating with Dynavax to evaluate the potential use of its CpG 1018 adjuvant as part of the VLA2001 vaccine.  This vaccine is expected to enter clinical studies by the end of 2020 and to potentially reach regulatory approval in the second half of 2021.

About the Novel Coronavirus SARS-CoV-2 and COVID-19 Disease

SARS-CoV-2 is a new coronavirus identified in late 2019 and belongs to a family of enveloped RNA viruses that include MERS and SARS, both of which caused serious human infections of respiratory system. The virus, which causes a disease named COVID-19, has never before been found in humans. Since this outbreak was first reported in late-2019, the virus has infected over 14 million people and has caused over 600,000 reported deaths (as of July 18, 2020). It has been declared a pandemic by the World Health Organization (WHO). Currently, there is no vaccine available for COVID-19.

Valneva Announces Positive Initial Results for Phase 2 Study of Lyme Disease Vaccine Candidate